Literature DB >> 24382003

Sclerostin inhibition for osteoporosis--a new approach.

Carolyn B Becker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24382003     DOI： 10.1056/NEJMe1315500

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Multipotential stromal cell abundance in cellular bone allograft: comparison with fresh age-matched iliac crest bone and bone marrow aspirate.

Authors:  Thomas G Baboolal; Sally A Boxall; Yasser M El-Sherbiny; Timothy A Moseley; Richard J Cuthbert; Peter V Giannoudis; Dennis McGonagle; Elena Jones
Journal:  Regen Med       Date:  2014-03-12       Impact factor: 3.806

Review 2.  Exploiting the WNT Signaling Pathway for Clinical Purposes.

Authors:  Mark L Johnson; Robert R Recker
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 3.  Inhibitors of sclerostin: emerging concepts.

Authors:  Matthew T Drake; Joshua N Farr
Journal:  Curr Opin Rheumatol       Date:  2014-07       Impact factor: 5.006

4.  Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone Axis.

Authors:  Paul Childress; Keith R Stayrook; Marta B Alvarez; Zhiping Wang; Yu Shao; Selene Hernandez-Buquer; Justin K Mack; Zachary R Grese; Yongzheng He; Daniel Horan; Fredrick M Pavalko; Stuart J Warden; Alexander G Robling; Feng-Chun Yang; Matthew R Allen; Venkatesh Krishnan; Yunlong Liu; Joseph P Bidwell
Journal:  Mol Endocrinol       Date:  2015-08-05

Review 5.  Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.

Authors:  Arti D Shah; Dolores Shoback; E Michael Lewiecki
Journal:  Int J Womens Health       Date:  2015-06-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.